YD Bio CEO buys 18,378 shares at $3.67

YD Bio Ltd’s CEO increased his stake with an open-market purchase and now beneficially owns large direct and indirect Ordinary Share positions.

Rhea-AI Filing Summary

YD Bio Ltd (YDES) director and CEO Dr. Ethan Shen reported purchasing 18,378 Ordinary Shares on September 4, 2026, in the open market at a weighted average price of $3.67 per share, with individual trade prices ranging from $3.50 to $3.70.

After this transaction, Dr. Shen holds 11,242,531 Ordinary Shares directly and 43,120,858 Ordinary Shares indirectly through YD Biopharma Holding Limited and related trust entities, of which he is the beneficial owner. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 18,378 shares

Net Buy 2 txns

Insider Shen Ethan PhD

Role CEO

Bought 18,378 shs ($67K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares F1	18,378	$3.67	$67K
holding	Ordinary Shares F2	--	--	--

Holdings After Transaction: Ordinary Shares — 11,242,531 shares (Direct); Ordinary Shares — 43,120,858 shares (Indirect, See Footnotes)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.50 to $3.70, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.
2. F2. The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.

Key Figures

Ordinary Shares purchased: 18,378 shares Weighted average purchase price: $3.67 per share Direct holdings after transaction: 11,242,531 shares +1 more

4 metrics

Ordinary Shares purchased 18,378 shares Open-market purchase on September 4, 2026

Weighted average purchase price $3.67 per share Open-market purchase on September 4, 2026; trades from $3.50 to $3.70

Direct holdings after transaction 11,242,531 shares Ordinary Shares held directly by Dr. Shen after September 4, 2026 purchase

Indirect holdings after transaction 43,120,858 shares Ordinary Shares held indirectly via YD Biopharma Holding Limited and related trust entities

Key Terms

weighted average price, beneficial owner, Ordinary Shares, indirect

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial owner financial

"Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares."

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Ordinary Shares financial

"The reported shares are held by YD Biopharma Holding Limited... number of Ordinary Shares purchased at each separate price"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

indirect financial

"The reported shares are held by YD Biopharma Holding Limited... which is wholly owned by The E820N Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did YDES CEO Dr. Ethan Shen report in this Form 4?

Dr. Ethan Shen reported purchasing 18,378 YD Bio Ltd (YDES) Ordinary Shares on September 4, 2026 in an open-market transaction at a weighted average price of $3.67 per share, with trade prices between $3.50 and $3.70.

How many YDES shares does the CEO hold directly after this transaction?

After the reported purchase, Dr. Ethan Shen holds 11,242,531 Ordinary Shares of YD Bio Ltd directly. This figure reflects his direct ownership position immediately following the September 4, 2026 transaction.

What is the CEO’s indirect ownership in YDES according to the filing?

The filing states that 43,120,858 Ordinary Shares are held indirectly through YD Biopharma Holding Limited, owned via E820N Assets Ltd. (BVI) and The E820N Trust. Dr. Shen is the settlor, protector and sole beneficiary of the trust and the beneficial owner of these shares.

Was the YDES CEO’s trade under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirming a plan, and there is no footnote stating that the September 4, 2026 transaction was made pursuant to a Rule 10b5-1 trading plan.

At what prices were the YDES shares traded in the CEO’s transaction?

The shares were traded at prices ranging from $3.50 to $3.70 per Ordinary Share. The reported $3.67 figure is a weighted average price across multiple individual trades within that price range.

Who is the beneficial owner of the indirectly held YDES shares?

The indirectly held 43,120,858 Ordinary Shares are owned through YD Biopharma Holding Limited and related entities, but the filing states that Dr. Ethan Shen is the beneficial owner of these shares as settlor, protector and sole beneficiary of The E820N Trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:01 PM Accepted by SEC EDGAR 09/08/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shen Ethan PhD

(Last) (First) (Middle)

C/O YD BIO LIMITED

12F., NO. 3, XINGNAN ST., NANGANG DIST.

(Street)

TAIPEI CITY TAIWAN 115001

(City) (State) (Zip)

TAIWAN

(Country)

2. Issuer Name and Ticker or Trading Symbol
YD Bio Ltd [ YDES ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/04/2026		P		18,378	A	$3.67(1)	11,242,531	D
Ordinary Shares								43,120,858	I	See Footnotes(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.50 to $3.70, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.

2. The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.

	/s/ Ethan Shen	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)